Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

Abstract:

INTRODUCTION:The treatment of lung cancer has radically changed over the last few years. The discovery of druggable oncogenic alterations and the introduction of immunotherapy have provided lung cancer patients with the possibility of more efficient and less toxic therapeutic alternatives than chemotherapy. In the case of lung squamous cell carcinoma (LSCC), the treatment progress is slower than adenocarcinoma, for which several targeted agents have been already approved. The standard first-line therapy for LSCC, in most sites of the world, is platinum-based chemotherapy. After disease progression, these patients now have novel treatment options, including antiangiogenic agents and immune checkpoint blockade. Areas covered: We provide a summary of the recent novelties for the second-line therapy of LSCC, emphasizing on the results of the most important clinical trials that have led to regulatory approvals. Expert commentary: Immune checkpoint inhibitors have changed the therapeutic algorithm for LSCC patients. Other treatment options in the second-line setting include ramucirumab in combination with docetaxel and afatinib. However, we still lack biomarkers to predict which patients could respond better to each treatment. Despite the identification of several actionable molecular alterations, there are no approved targeted agents specific for advanced LSCC. Results from ongoing biomarker-driven studies are eagerly awaited to establish effective treatments for molecularly selected subgroups of patients.

journal_name

Expert Rev Respir Med

authors

Lazzari C,Karachaliou N,Gregorc V,Bulotta A,Gonzalez-Cao M,Verlicchi A,Altavilla G,Rosell R,Santarpia M

doi

10.1080/17476348.2017.1326822

subject

Has Abstract

pub_date

2017-06-01 00:00:00

pages

469-479

issue

6

eissn

1747-6348

issn

1747-6356

journal_volume

11

pub_type

杂志文章,评审
  • The management of infection with Mycobacterium tuberculosis in young children post-2015: an opportunity to close the policy-practice gap.

    abstract:INTRODUCTION:The treatment of infection with Mycobacterium tuberculosis in young children is supported by universal policy based on strong rationale and evidence of effectiveness, but has rarely been implemented in tuberculosis endemic countries. Areas covered: This review highlights a number of important recent develo...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2016.1267572

    authors: Graham SM

    更新日期:2017-01-01 00:00:00

  • Combination therapy in pulmonary arterial hypertension: do we have the right strategy?

    abstract::The management of pulmonary hypertension has already incorporated the use of multiple therapies into routine practice. Available therapies act principally through vasodilatation of the pulmonary arterial circulation through well-delineated mechanisms, although right ventricular function determines function and prognos...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.11.13

    authors: Mukherjee B,Howard L

    更新日期:2011-04-01 00:00:00

  • Budesonide/formoterol in the treatment of asthma.

    abstract::Budesonide/formoterol is a combination of an inhaled corticosteroid plus a long-acting beta(2)-agonist available as a dry-powder inhaler for the indication of asthma and chronic obstructive pulmonary disease in various countries outside of the USA and as a pressurized metered-dose inhaler in the USA for the indication...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.2.5.551

    authors: Lee C,Corren J

    更新日期:2008-10-01 00:00:00

  • Thirty-five alternatives to positive airway pressure therapy for obstructive sleep apnea: an overview of meta-analyses.

    abstract:INTRODUCTION:Positive airway pressure (PAP) devices are generally considered to be the first-line treatment of choice for most adults with obstructive sleep apnea (OSA). However, there are several alternatives. It is important for patients and their sleep providers to be aware of the most up-to-date information regardi...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1080/17476348.2018.1522253

    authors: Camacho M,Chang ET,Neighbors CLP,Noller MW,Mack D,Capasso R,Kushida CA

    更新日期:2018-11-01 00:00:00

  • BLP-25 liposomal vaccine: a promising potential therapy in non-small-cell lung cancer.

    abstract::Despite marginal improvements in survival gained from multimodality treatment, long-term survival rates remain low for lung cancer, which remains the leading cause of cancer-related mortality in North America. BLP25 liposomal (L-BLP25) vaccine (Stimuvax) is a promising liposomal vaccine designed to generate an immune ...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.2.1.37

    authors: Powell E,Chow LQ

    更新日期:2008-02-01 00:00:00

  • Mesenchymal stem cells for repair of the airway epithelium in asthma.

    abstract::The airway epithelium is constantly faced with inflammatory and potentially injurious stimuli. Following damage, rapid repair mechanisms involving proliferation and differentiation of resident progenitor and stem cell pools are necessary in order to maintain a protective barrier. In asthma, evidence pointing to a comp...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.10.72

    authors: Knight DA,Rossi FM,Hackett TL

    更新日期:2010-12-01 00:00:00

  • Growing old with asthma: what are the changes and challenges?

    abstract::Asthma is a disease that affects approximately 7% of adults residing in the USA; the prevalence is even greater in children and approaches 10%. The CDC has reported that the overall prevalence of lifetime asthma is 10.5%. New-onset asthma is most often seen in children and is associated with atopy; however, the majori...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.10.12

    authors: Braman SS

    更新日期:2010-04-01 00:00:00

  • Home oxygen therapy: evidence versus reality.

    abstract:INTRODUCTION:LTOT is a well-established treatment option for hypoxemic patients. Scientific evidence for its benefits of LTOT dates back to the 1980s, when two randomized controlled trials showed prolonged survival in COPD-patients undergoing LTOT for at least 15 hours/day. In contrast, the potential benefits of LTOT i...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2017.1325323

    authors: Magnet FS,Storre JH,Windisch W

    更新日期:2017-06-01 00:00:00

  • Role of dendritic cells in the lung: in vitro models, animal models and human studies.

    abstract::Dendritic cells (DCs) are the most potent antigen-presenting cells in the human lung and are now recognized as crucial initiators of immune responses in general. They are arranged as sentinels in a dense surveillance network inside and below the epithelium of the airways and alveoli, where they are ideally situated to...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.2.2.215

    authors: Blank F,von Garnier C,Obregon C,Rothen-Rutishauser B,Gehr P,Nicod L

    更新日期:2008-04-01 00:00:00

  • Role of caveolin-1 in asthma and chronic inflammatory respiratory diseases.

    abstract::Caveolin-1 (Cav-1) is the major protein present in invaginations of the plasma membrane of cells known as caveolae. Cav-1 is expressed in numerous resident and inflammatory cells implicated in the pathogenesis of asthma and chronic inflammatory respiratory diseases including chronic obstructive pulmonary disease. A re...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/17476348.2014.905915

    authors: Royce SG,Le Saux CJ

    更新日期:2014-06-01 00:00:00

  • Perspectives in adjuvant chemotherapy in NSCLC.

    abstract::In 2007 the long-term outcome of lung cancer is still disappointing, with a 5-year survival rate not exceeding 15%. However, small but significant improvements in survival times have been achieved in the last decade. This progress has been achieved through the improvement of surgical techniques and following the intro...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.1.1.99

    authors: Selvaggi G,Scagliotti GV

    更新日期:2007-08-01 00:00:00

  • Genetics and genomics in human lung transplantation.

    abstract::Lung transplantation is the only effective treatment for many advanced lung diseases. However, long-term survival after transplantation remains relatively poor, thus limiting the application of lung transplantation to patients with end-stage disease only. Acute and chronic rejection is the main reason for allograft fa...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.1.2.271

    authors: Garantziotis S,Palmer SM

    更新日期:2007-10-01 00:00:00

  • Bronchiolitis: adopting a unifying definition and a comprehensive etiological classification.

    abstract::Bronchiolitis is an inflammatory and potentially fibrosing condition affecting mainly the intralobular conducting and transitional small airways. Secondary bronchiolitis participates in disease process of the airways and/or the surrounding lobular structures in the setting of several already defined clinical entities,...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.13.21

    authors: Papiris SA,Malagari K,Manali ED,Kolilekas L,Triantafillidou C,Baou K,Rontogianni D,Bouros D,Kagouridis K

    更新日期:2013-06-01 00:00:00

  • Pathophysiology, management and treatment of smoke inhalation injury.

    abstract::Smoke inhalation injury continues to increase morbidity and mortality in burn patients in both the third world and industrialized countries. The lack of uniform criteria for the diagnosis and definition of smoke inhalation injury contributes to the fact that, despite extensive research, mortality rates have changed li...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/ERS.09.21

    authors: Rehberg S,Maybauer MO,Enkhbaatar P,Maybauer DM,Yamamoto Y,Traber DL

    更新日期:2009-06-01 00:00:00

  • Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis.

    abstract:INTRODUCTION:Idiopathic pulmonary fibrosis (IPF) is a chronic, debilitating, fibrotic lung disease leading to respiratory failure, and ultimately to death. It is characterized by marked heterogeneity regarding its clinical course. Despite significant progress in the understanding of its pathogenesis, the course of the ...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2019.1553620

    authors: Inchingolo R,Varone F,Sgalla G,Richeldi L

    更新日期:2019-01-01 00:00:00

  • Spinal cord injury and diaphragm neuromotor control.

    abstract::Introduction: Neuromotor control of diaphragm muscle and the recovery of diaphragm activity following spinal cord injury have been narrowly focused on ventilation. By contrast, the understanding of neuromotor control for non-ventilatory expulsive/straining maneuvers (including coughing, defecation, and parturition) is...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1080/17476348.2020.1732822

    authors: Fogarty MJ,Sieck GC

    更新日期:2020-05-01 00:00:00

  • Personalizing and targeting therapy for COPD: the role of molecular and clinical biomarkers.

    abstract::Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease characterized by persistent airflow limitation. It is the third leading cause of death worldwide, and there are currently no curative strategies for this disease. Many factors contribute to COPD susceptibility, progression and exacerbations. These...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/17476348.2013.842468

    authors: Goh F,Shaw JG,Savarimuthu Francis SM,Vaughan A,Morrison L,Relan V,Marshall HM,Dent AG,O'Hare PE,Hsiao A,Bowman RV,Fong KM,Yang IA

    更新日期:2013-12-01 00:00:00

  • Risks associated with lung transplantation in cystic fibrosis patients.

    abstract:INTRODUCTION:Survival after lung transplantation lags behind outcomes of other solid organ transplants, and complications from lung transplant are the second most common cause of death in cystic fibrosis. Evolving surgical techniques, therapeutics, and perioperative management have improved short-term survival after lu...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2018.1522254

    authors: Li SS,Tumin D,Krone KA,Boyer D,Kirkby SE,Mansour HM,Hayes D Jr

    更新日期:2018-11-01 00:00:00

  • Management of pleural infections.

    abstract:INTRODUCTION:The management of infected pleural effusion is complex. Therapeutic resolution requires determining the following: appropriate antibiotic regimen, the need for pleural drainage, the optimal drainage tube size, and the need for intrapleural therapy or surgery. Areas covered: An updating of the latest advanc...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2018.1475234

    authors: Ferreiro L,Porcel JM,Bielsa S,Toubes ME,Álvarez-Dobaño JM,Valdés L

    更新日期:2018-06-01 00:00:00

  • Asthma-related comorbidities.

    abstract::Asthma is often associated with various comorbidities. The most frequently reported asthma comorbid conditions include rhinitis, sinusitis, gastroesophageal reflux disease, obstructive sleep apnea, hormonal disorders and psychopathologies. These conditions may, first: share a common pathophysiological mechanism with a...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.11.34

    authors: Boulet LP,Boulay MÈ

    更新日期:2011-06-01 00:00:00

  • Tezacaftor and ivacaftor for the treatment of cystic fibrosis.

    abstract::Introduction: Cystic fibrosis (CF) is a complex, multi-system, genetic disease affecting over 70,000 people worldwide. The underlying defect is a mutation in the CFTR gene. Dysfunctional CFTR protein results in abnormal anion movement across epithelial membranes in affected organs. There has been a paradigm shift in C...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2020.1682998

    authors: Paterson SL,Barry PJ,Horsley AR

    更新日期:2020-01-01 00:00:00

  • What is the importance of classifying Aspergillus disease in cystic fibrosis patients?

    abstract::Aspergillus species are commonly isolated from lower respiratory tract samples of patients with cystic fibrosis (CF) and markers of immunological sensation to Aspergillus are frequently encountered in this group of patients; however, the contribution of Aspergillus to CF lung disease outside of the typical complicatio...

    journal_title:Expert review of respiratory medicine

    pub_type: 社论

    doi:10.1586/17476348.2014.915751

    authors: Jones AM,Horsley A,Denning DW

    更新日期:2014-08-01 00:00:00

  • Vitamin D and omega-3 polyunsaturated fatty acid supplementation in athletes with exercise-induced bronchoconstriction: a pilot study.

    abstract:OBJECTIVE:The aim of this pilot study was to determine the combined effect of vitamin D and omega-3 polyunsaturated fatty acid (PUFA) supplementation on airway function and inflammation in recreational athletes with exercise-induced bronchoconstriction (EIB). METHODS:Ten recreational athletes with EIB participated in ...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.2015.1036032

    authors: Price OJ,Hull JH,Howatson G,Robson-Ansley P,Ansley L

    更新日期:2015-06-01 00:00:00

  • Exercise-based evaluations and interventions for pulmonary hypertension with connective tissue disorders.

    abstract:INTRODUCTION:Exercise intolerance is a common and often significant limitation in pulmonary arterial hypertension (PAH). This intolerance greatly affects the quality of life and function of the individual with PAH, irrespective of its etiology. In PAH associated with connective tissue disorders (PAH-CTD), exercise into...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2018.1481393

    authors: Babu AS,Morris NR,Arena R,Myers J

    更新日期:2018-07-01 00:00:00

  • Inhaled treprostinil for the treatment of pulmonary arterial hypertension.

    abstract::Treprostinil is a prostacyclin derivative approved for the treatment of pulmonary arterial hypertension by intravenous, subcutaneous and inhalational administration. Unlike its precursor epoprostenol, treprostinil is chemically stable at room temperature and neutral pH, and its plasma half-life is longer. In addition ...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.12.23

    authors: LeVarge BL,Channick RN

    更新日期:2012-06-01 00:00:00

  • Improving quality of life for patients with terminal respiratory disease.

    abstract::Chronic respiratory disease is an increasingly prevalent cause of life-limiting illness. Care for patients with terminal respiratory diseases has historically focused on disease-modifying therapies, many of which have little impact on life expectancy. This exclusive focus can detract from attention to patient-physicia...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/ers.09.47

    authors: Isaac M,Curtis JR

    更新日期:2009-12-01 00:00:00

  • Current and future molecular approaches in the diagnosis of cystic fibrosis.

    abstract:INTRODUCTION:Cystic Fibrosis is among the first diseases to have general population genetic screening tests and one of the most common indications of prenatal and preimplantation genetic diagnosis for single gene disorders. During the past twenty years, thanks to the evolution of diagnostic techniques, our knowledge of...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2018.1457438

    authors: Bergougnoux A,Taulan-Cadars M,Claustres M,Raynal C

    更新日期:2018-05-01 00:00:00

  • Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease.

    abstract::During the last decade, there have been major advances in knowledge of the effects of oxygen therapy in patients with acute exacerbations of chronic obstructive pulmonary disease. This includes a randomised controlled trial of oxygen therapy in the pre-hospital setting, which showed that high concentration oxygen ther...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/17476348.2015.1016503

    authors: Pilcher J,Weatherall M,Perrin K,Beasley R

    更新日期:2015-06-01 00:00:00

  • Recent advances in pediatric asthma treatment.

    abstract::Although wheezing illness is at its most prevalent in infancy and early childhood, its self-limiting nature in the majority poses considerable challenges in offering a long-term prognosis and in initiating long-term prophylaxis. Many of the established treatments in adults have not been adequately assessed in children...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/ers.09.2

    authors: Helms PJ

    更新日期:2009-04-01 00:00:00

  • Treatment in resectable, locally advanced NSCLC: which is the best approach?

    abstract::Non-small-cell lung cancer is the most common cause of cancer-related death worldwide. Surgery remains the cornerstone of treatment for localized, resectable lung cancer, although advanced stages are associated with a high risk of developing distant metastases. Large randomized trials have demonstrated an improvement ...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.2.5.655

    authors: Kueng MM,Betticher DC

    更新日期:2008-10-01 00:00:00